PCG
SRPT icon

Private Capital Group’s Sarepta Therapeutics SRPT Stock Holding History

Private Capital Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60
Closed -$6K – 2187
2021
Q3 		$6K Buy
60
+41
+216% +$3.16K ﹤0.01% 1528
2021
Q2 		$2K Buy
+19
New +$1.44K ﹤0.01% 1878
2019
Q4 		– Sell
-72
Closed -$5K – 2173
2019
Q3 		$5K Buy
+72
New +$8.5K ﹤0.01% 1685
2018
Q4 		– Sell
-9
Closed -$1K – 2328
2018
Q3 		$1K Buy
+9
New +$1.23K ﹤0.01% 2096

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Private Capital Group's SRPT Position: Q4 2021 in Review

Private Capital Group sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 60 shares — an estimated $6K sold.

Private Capital Group first reported a position in SRPT in Q3 2018 and held it in 4 quarters. The position peaked at $6K in Q3 2021. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

  • Private Capital Group reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Private Capital Group sold 60 Sarepta Therapeutics shares in Q4 2021, an estimated $6K.
  • Private Capital Group first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 4 quarters.
  • Private Capital Group's Sarepta Therapeutics position peaked at $6K in Q3 2021.
  • 343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Private Capital Group's 13F filing for Q4 2021, filed 24 Jan 2022.